Angelini to buy Catalyst in $4B play for rare neuro drugs

Angelini Acquires Catalyst for $4.1B to Boost Rare Neuro Portfolio

Angelini Pharma announced its intent to acquire Catalyst Pharmaceuticals in a $4.1 billion deal on May 7, 2026. This acquisition will provide the Italian drugmaker with a portfolio of three approved medicines for rare central nervous system disorders, including Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for seizures, and Agamree for Duchenne muscular dystrophy. The strategic move grants Angelini significant entry into the U.S. market and aims to establish a new therapeutic platform in rare diseases, aligning with a broader industry trend of increased investment in neuroscience.

• Angelini Pharma's acquisition of Catalyst Pharmaceuticals is valued at $4.1 billion, with a payment of $31.50 per share, representing a 21% premium over Catalyst's previous day's closing price. Catalyst reported $589 million in revenue last year and provided 2026 financial guidance of $615 million to $645 million, driven by the strong performance of its Firdapse and Agamree franchises.
• The deal integrates Catalyst's three marketed CNS drugs—Firdapse, Fycompa, and Agamree—into Angelini's portfolio. This strategic move is crucial for Angelini, as it provides a significant entry point into the U.S. pharmaceutical market, allowing the company to expand its scale and commercial capabilities in a key global region. The transaction is expected to close in the third quarter of 2026.
• Angelini aims to leverage Catalyst's portfolio and commercial infrastructure to develop a next-generation therapeutic platform focused on rare diseases, complementing its existing expertise in brain health. This acquisition is noted as one of the larger M&A deals in 2026, reflecting a broader industry trend of increasing pharmaceutical investment in neuroscience, with other major players also acquiring CNS drugmakers this year.

Addressing Unmet Needs in Lambert-Eaton Myasthenic Syndrome

Current treatment approaches for Lambert-Eaton myasthenic syndrome face significant limitations that impact both clinical management and patient outcomes. The therapeutic landscape is characterized by insufficient evidence, limited treatment options, and diagnostic complexities that challenge optimal patient care.

• Insufficient evidence base: Only three randomized controlled trials have examined treatments for Lambert-Eaton myasthenic syndrome, with total enrollment of just 38 patients for 3,4-diaminopyridine studies and 9 patients for intravenous immunoglobulin trials, providing inadequate data to quantify treatment effects

• Limited duration of therapeutic benefit: Intravenous immunoglobulin provides clinical improvement for only up to eight weeks, while 3,4-diaminopyridine can have very short-lasting effects of less than one hour in some patients, leading to irregular dosing patterns

• Untested therapeutic options: Several potential treatments including plasma exchange, steroids, and immunosuppressive agents have not been evaluated in randomized controlled trials, leaving clinicians without evidence-based guidance for these interventions

• Diagnostic challenges: Atypical presentations dominated by severe bulbar dysfunction without limb involvement or respiratory failure can mimic myasthenia gravis and other neuromuscular junction disorders, leading to delayed diagnosis that can persist for many years

• Methodological limitations: Meta-analysis of treatment outcomes is not possible due to marked differences in study comparisons, endpoints, and lack of individual patient data across trials

• Lack of long-term studies: Proper long-term efficacy and cost-benefit analyses are needed, particularly for chronic intravenous immunoglobulin treatment, to establish optimal therapeutic strategies

• Individual treatment complexity: The therapeutic approach in individual patients appears difficult to standardize, with pyridostigmine showing no additional benefit when combined with 3,4-diaminopyridine

Expanding Firdapse's Potential Beyond Lambert-Eaton Myasthenic Syndrome

Firdapse (amifampridine phosphate) has demonstrated potential therapeutic value beyond its approved indication for Lambert-Eaton myasthenic syndrome. Clinical investigation has focused primarily on neuromuscular conditions where potassium channel blocking may provide functional benefits. The most notable expansion has been into spinal muscular atrophy, where controlled trials have yielded promising safety and efficacy data.

• Spinal Muscular Atrophy Type 3 - A Phase 2 randomized, double-blind, placebo-controlled crossover study (SMA-001, NCT03781479) evaluated amifampridine in 13 ambulatory patients with SMA Type 3 who were treatment-naive for SMN-enhancing medications

• Novel crossover intervention design - The trial employed a run-in phase for dose optimization followed by randomization of responders (≥3-point HFMSE improvement) to a 28-day double-blind crossover phase comparing amifampridine versus placebo

• Clinically meaningful efficacy outcomes - Treatment demonstrated statistically significant improvement in the Hammersmith Functional Motor Score Expanded (mean difference 0.792; 95% CI 0.22-1.37; p=0.0083) compared to placebo, providing Class II evidence of safety and efficacy

• Favorable safety profile - No serious adverse events were reported during the trial, with transient paresthesia occurring in 33.3% of patients as the only treatment-related adverse event

• Targeted patient population - The study focused on ambulatory patients (walking unaided ≥30 meters) with mean age 34.5 years, representing a specific SMA Type 3 phenotype that may be most responsive to potassium channel modulation

The Evolving Treatment Landscape for Lambert-Eaton Myasthenic Syndrome

The treatment landscape for Lambert-Eaton myasthenic syndrome has become increasingly standardized around aminopyridine-based therapies, with substantial real-world evidence supporting their efficacy. The European LEMS registry, encompassing 96 patients across 30 centers in four countries, demonstrated that 3,4-diaminopyridine phosphate (3,4-DAPP) provides sustained or improved functioning, while traditional 3,4-diaminopyridine (3,4-DAP) and other treatments showed more inconsistent outcomes. This large-scale registry data confirmed the safety profile of aminopyridines, with treatment-related adverse events reported in 33.3% of participants and serious adverse events in 8.3%, while identifying no new safety signals.

Recent clinical effectiveness studies have provided robust quantitative evidence for amifampridine's therapeutic benefit in non-neoplastic LEMS patients. A 2024 study of 14 patients demonstrated universal improvement in Quantitative Myasthenia Gravis scores, with a mean improvement of 5.1 ± 2.0 points and 85.7% of patients achieving clinically meaningful improvement of ≥3 points. Notably, treatment effectiveness showed no correlation with disease duration, suggesting benefit regardless of diagnostic delay. Objective measures including forced vital capacity, hand grip strength, and compound muscle action potential amplitude all showed statistically significant improvements, while 64.3% of patients achieved corticosteroid dose reduction.

The treatment paradigm has evolved to incorporate more sophisticated immunotherapeutic approaches and recognition of complex presentations. Cases of LEMS induced by immune checkpoint inhibitors have emerged, requiring combination therapy with steroid pulse and intravenous immunoglobulin following drug discontinuation. Plasmapheresis has demonstrated significant efficacy in atypical presentations, particularly those with severe bulbar dysfunction resistant to standard treatments. Additionally, cholinesterase inhibitors have shown dramatic responses in select patients with P/Q-type voltage-gated calcium channel antibody-positive LEMS, suggesting potential for personalized treatment strategies based on antibody profiles.

Angelini's Strategic Entry into the U.S. Rare CNS Market

The acquisition of Catalyst Pharmaceuticals by Angelini Pharma represents a pivotal strategic move, propelling the Italian drugmaker into the lucrative U.S. rare central nervous system (CNS) market. This $4.1 billion deal secures a portfolio of three approved medicines, establishing a new therapeutic platform aligned with the broader industry trend of increased investment in neuroscience.

At the core of this expansion is Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), an orphan drug supported by Class I evidence demonstrating significant efficacy and long-term tolerability. Its position as a drug of choice for LEMS provides a stable foundation. However, the historical context of amifampridine's prior availability as a compounded medication highlights the ongoing tension between orphan drug development and the pragmatic use of existing therapies, a dynamic that could influence future market perceptions or regulatory pathways.

Fycompa, a newer-generation antiepileptic drug (AED), offers a novel mechanism of action as a selective AMPA receptor antagonist, providing an important option for patients with focal and primary generalized tonic-clonic seizures, including those with drug-resistant epilepsy. Its once-daily formulation can enhance patient compliance, and studies indicate it contributes to better treatment compliance and lower healthcare resource utilization compared to older AEDs. Yet, the competitive landscape is evolving rapidly; real-world data suggest that newer AEDs like cenobamate demonstrate significantly higher retention rates than perampanel, indicating potential market share challenges. Furthermore, its past removal from the German market due to a perceived lack of additional therapeutic value underscores potential market access hurdles.

Agamree (vamorolone) represents a promising advance in DMD treatment. As a dissociative corticosteroid, it aims to provide the anti-inflammatory benefits of standard corticosteroids while mitigating severe adverse effects such as growth stunting, a critical concern in pediatric populations. Clinical trials have shown maintained motor outcomes and a reversal of prednisone-induced bone morbidities upon transition to vamorolone. While offering a differentiated safety profile, the long-term efficacy and safety data for vamorolone, like many newer DMD therapies, remain limited, and direct comparisons to all existing standard-of-care steroids, such as deflazacort, are still needed. This necessitates ongoing monitoring and robust post-market studies to solidify its long-term value proposition.

This acquisition positions Angelini to capitalize on the high unmet medical needs within rare CNS disorders, but success will hinge on navigating competitive pressures, demonstrating sustained long-term value, and effectively managing regulatory and market access complexities inherent in this specialized therapeutic area.